No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration with emtricitabine/tenofovir-DF has not been studied, but based on metabolism and clearance a clinically significant interaction is unlikely. No clinically significant interactions were observed when emtricitabine and tenofovir-DF (with efavirenz) and glecaprevir/pibrentasvir were coadministered. No dose adjustment is required.
Coadministration of glecaprevir/pibrentasvir (300/120 mg once daily) and efavirenz/emtricitabine/tenofovir-DF (600/200/300 mg once daily) was studied in 7 HIV-positive subjects. Efavirenz Cmax, AUC and Ctrough increased by 6%, 3% and 1%, respectively; emtricitabine Cmax, AUC and Ctrough increased by 4%, 7% and 13%, respectively; tenofovir Cmax, AUC and Ctrough increased by 22%, 29% and 38%, respectively. The study design did not allow evaluation of the effect on glecaprevir and pibrentasvir within the study subjects, but glecaprevir and pibrentasvir exposures were ≥47% lower than observed for glecaprevir/pibrentasvir alone in the other antiretroviral interaction studies, possibly due to induction of CYP3A and/or P-gp by efavirenz.
Interactions of glecaprevir and pibrentasvir coadministered with human immunodeficiency virus antiretrovirals. Kosloski MP, Oberoi R, Wang S, et al. J Infect Dis. 2020;221(2):223-231.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking